Moleculin Biotech, Inc. (NASDAQ:MBRX) Sees Large Increase in Short Interest

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 358,088 shares, an increase of 108.8% from the December 31st total of 171,538 shares. Based on an average daily volume of 156,481 shares, the short-interest ratio is presently 2.3 days. Currently, 17.9% of the shares of the stock are short sold. Currently, 17.9% of the shares of the stock are short sold. Based on an average daily volume of 156,481 shares, the short-interest ratio is presently 2.3 days.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MBRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, January 22nd. Roth Mkm reissued a “buy” rating on shares of Moleculin Biotech in a research report on Monday, December 15th. Finally, HC Wainwright restated a “buy” rating and issued a $22.00 price target (up previously from $4.00) on shares of Moleculin Biotech in a research report on Thursday, December 11th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Moleculin Biotech presently has a consensus rating of “Moderate Buy” and an average target price of $61.00.

Moleculin Biotech Trading Up 0.2%

Moleculin Biotech stock opened at $4.29 on Friday. The firm has a market capitalization of $8.75 million, a price-to-earnings ratio of -0.13 and a beta of 1.62. The firm’s fifty day moving average price is $4.94 and its two-hundred day moving average price is $10.16. Moleculin Biotech has a 1-year low of $3.13 and a 1-year high of $91.25.

Moleculin Biotech (NASDAQ:MBRX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.07. On average, research analysts forecast that Moleculin Biotech will post -7.98 EPS for the current year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.